Alert detail
FDA Approval: MIMRYLO (RUSFERTIDE ACETATE) — Type 1 - New Molecular Entity
Policy ID: FDA-NDA220605Specialty: HematologyAdded: 9/3/2026Effective: August 28, 2026billing update
What changed
New subcutaneous Part B injectable; watch for J-code assignment.
Who’s affected: Hematology billing teams · Effective: August 28, 2026
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.